villanova health summit

Host: Matt Birnholz, MD

Joining host Dr. Matt Birnholz is Sarah Marchal Murray, Chief Operating Officer at The END Fund, a private philanthropic initiative dedicated to controlling and eliminating neglected tropical diseases (NTDs). Over 1.4 billion people globally are affected by one or more of the most common NTDs, including 875 million children. The END Fund focuses on tackling the five most prevalent NTDs: intestinal worms,schistosomiasis,lymphatic filariasis,trachoma, and river blindness.

Host: Matt Birnholz, MD

Joining host Dr. Matt Birnholz is Sarah Marchal Murray, Chief Operating Officer at The END Fund, a private philanthropic initiative dedicated to controlling and eliminating neglected tropical diseases (NTDs). Over 1.4 billion people globally are affected by one or more of the most common NTDs, including 875 million children. The END Fund focuses on tackling the five most prevalent NTDs: intestinal worms,schistosomiasis,lymphatic filariasis,trachoma, and river blindness.

Host: Matt Birnholz, MD

Joining host Dr. Matt Birnholz is Sarah Marchal Murray, Chief Operating Officer at The END Fund, a private philanthropic initiative dedicated to controlling and eliminating neglected tropical diseases (NTDs). Over 1.4 billion people globally are affected by one or more of the most common NTDs, including 875 million children. The END Fund focuses on tackling the five most prevalent NTDs: intestinal worms,schistosomiasis,lymphatic filariasis,trachoma, and river blindness.

Host: Matt Birnholz, MD

Dr. Matt Birnholz sits down with Dr. Sarah-Vaughan Brakman, Clinical Medical Ethicist and Associate Professor of Philosophy at Villanova University, to discuss how the MCAT has changed its selection process to ultimately prepare medical students to become more humanistic doctors. Dr. Brakman details the recent MCAT transition to include modern issues in medical ethics and philosophy within exams, reflecting important changes in medical school selection processes.

Host: Matt Birnholz, MD

Dr. Matt Birnholz welcomes Patrick Higgins, President and Chief Operating Officer of Tekmira Pharmaceuticals, to discuss his research team's inspiring journey toward developing a cure for Hepatitis C. Following this success, Tekmira aims to accelerate the pace of research and development for a novel Hepatitis B drug.

Host: Matt Birnholz, MD

Dr. Matt Birnholz welcomes Patrick Higgins, President and Chief Operating Officer of Tekmira Pharmaceuticals, to discuss his research team's inspiring journey toward developing a cure for Hepatitis C. Following this success, Tekmira aims to accelerate the pace of research and development for a novel Hepatitis B drug.

Host: Matt Birnholz, MD

Dr. Matt Birnholz welcomes Patrick Higgins, President and Chief Operating Officer of Tekmira Pharmaceuticals, to discuss his research team's inspiring journey toward developing a cure for Hepatitis C. Following this success, Tekmira aims to accelerate the pace of research and development for a novel Hepatitis B drug.

Host: Matt Birnholz, MD

Dr. Matt Birnholz welcomes Patrick Higgins, President and Chief Operating Officer of Tekmira Pharmaceuticals, to discuss his research team's inspiring journey toward developing a cure for Hepatitis C. Following this success, Tekmira aims to accelerate the pace of research and development for a novel Hepatitis B drug.